[Clinical development of genetically modified T cell therapies]

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Genetically modified T cell therapies, such as chimeric antigen receptor (CAR)-T and T cell receptor (TCR)-T cell therapies, are emerging as significant cancer treatments, particularly for hematological malignancies.
• These advanced therapies are increasingly integrated into clinical practice, offering new hope for patients with difficult-to-treat cancers.

Purpose of the Study:

• To review the current status and future prospects of genetically modified T cell therapy development.
• To discuss the drug discovery ecosystem for cell therapy platforms, with a specific emphasis on Japan.

Main Methods:

• Literature review of genetically modified T cell therapies.
• Analysis of challenges and achievements in CAR-T and TCR-T cell development.
• Discussion of the cell therapy drug discovery landscape.

Main Results:

• CAR-T and TCR-T cell therapies face challenges like relapsed/refractory disease, adverse events, manufacturing issues, and high costs.
• Significant progress includes positive clinical responses in CAR-T cell trials and the FDA approval of a TCR-T cell product for synovial sarcoma.

Conclusions:

• Despite challenges, genetically modified T cell therapies represent a rapidly advancing field with significant therapeutic potential.
• Further development and strategic ecosystem support, particularly in Japan, are crucial for the future of cell therapy.